The Sabin Vaccine Institute supports innovative technologies and approaches in vaccine research and development to combat infectious and emerging threats to global health.  Sabin leverages the expertise of partners in the academic, public and private sectors, and promotes open-source research.

For more than a decade, Sabin conducted research to develop new, low-cost vaccines for diseases impacting the world's most neglected and vulnerable populations, including the first and only vaccine candidate for human hookworm to be assessed in clinical trials, and vaccine candidates for intestinal schistosomiasis infection and Chagas disease. From 2011 to 2017, Sabin partnered with the Baylor College of Medicine and Texas Children’s Hospital in Houston, Texas, to carry out this work. Baylor College of Medicine continues this research as of May 2017 at the Texas Children’s Hospital’s Center for Vaccine Development.

Sabin remains committed to supporting research to identify innovative solutions that will improve the lives of millions through immunization. With new management and a renewed dedication to improving human health through immunization, Sabin is evaluating opportunities to engage in innovative research and form new partnerships.